Key Highlights

Risk & Performance

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

20%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

2 recruiting

Phase 1

2(66.7%)

Phase 3

1(33.3%)

3Total

Phase 1(2)

Phase 3(1)

Loading network data...

Showing 5 of 5 trials

A Study to Investigate the Efficacy and Safety of Bemdaneprocel in Adults Who Have Parkinson's Disease

Role: lead

A Study to Investigate the Safety of OpCT-001 in Adults Who Have Primary Photoreceptor Disease (CLARICO)

Role: lead

Phase 1 Safety and Tolerability Study of MSK-DA01 Cell Therapy for Advanced Parkinson's Disease

Role: lead

Noninterventional Study Evaluating Parkinson's Disease Diary Use

Role: lead

Continued Evaluation of Patients With Parkinson's Disease Who Previously Received BRT-DA01

Role: lead

All 5 trials loaded